Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.FBRX · Entity 9529 | Director | June 01, 2022 | June 02, 2022 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | July 05, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date June 01, 2022 · Filed June 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2032-06-01 | Direct | 25,000 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 25,000 · Balance 25,000 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022.
STRATA Skin Sciences, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 89,894 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 36,408 · Balance 89,894 F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2023 Filed Jul 7, 2023 16:08 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 36,408 | $1.03 | $37,500.24 |
DisclosureSEC source: 0001051514-23-000031 · form4.xml · nonDerivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,894 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:04 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 40,541 | $0.93 | $37,500.43 |
DisclosureSEC source: 0001051514-22-000073 · form4.xml · nonDerivative · entry 2 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,486 F2 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 1, 2022. The Restricted Stock Units will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 16:04 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 9,756 | $0.96 | $9,375.52 |
DisclosureSEC source: 0001051514-22-000073 · form4.xml · nonDerivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,945 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on June 30, 2022. The Restricted Stock Units vest at 100% upon issue. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:13 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-033631 · doc4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:03 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Restricted Stock Units · Derivative | 3,189 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001051514-22-000052 · form4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,189 Underlying: Common Stock · 3,189 shares Expires 2032-03-31 Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 22:06 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-012747 · doc4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the one (1) year anniversary of the Date of Grant. "Date of Grant" shall mean February 23, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 10:23 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Non-Qualified Stock Options · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001051514-22-000023 · form4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-14 F1 · shares: Options fully vest on the first anniversary, February 14, 2023. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:30 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $35.54 | $0.00 |
DisclosureSEC source: 0000899243-21-021414 · doc4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-28 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean May 28, 2021. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:52 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016933 · doc4.xml · derivative · entry 1 Walker Patricia S · CIK 0001303798 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.